Mission Statement


Research at the Division of Pharmacology and Toxicology is driven by the motivation to decipher the dynamic mechanisms underlying aging and disease, such as chronic pain. To this end, we combine a diverse set of methods ranging from molecular biology and biochemistry,  electrophysiology,  primary cell culture and preclinical mouse models to molecular modelling and quantitative proteomics. Our goal is to identify novel therapeutic targets that have the potential to improve current treatments of studied diseases.



Our latest work about neuroimmune interactions in the context of neuropathic pain has been published in Cell Reports. CONGRATULATIONS to all authors and the great team of collaborators!

“Tmem160 contributes to the establishment of discrete nerve injury-induced pain behaviors in male mice”



In November 2021, David Gomez Varela PhD has joined our division as a Senior Scientist. Building on his experience in different leading positions (most recently as a Max Planck group leader: gomezvarelalab.em.mpg.de), David will establish and surveil interdisciplinary research projects to better understand the etiology and pathophysiology underlying aging and disease.


In October 2021, Assistant Professor Marietta Zille, PhD has joined our division. Her lab aims to better understand the etiology and pathophysiology of cerebrovascular disease and brain aging to identify novel druggable targets and to develop innovative therapies for prevention, cytoprotection, regeneration, and recovery of motor and cognitive function.


New research direction at our Department: From September 2020 on the research group of Prof. Manuela Schmidt will join our Department. Our new research group will use systems biology to address somatosensation in health, development (aging) and disease (chronic pain). Further information will follow.


New FWF Zukunftskolleg focuses on peptide drug candidates


"Dr. Eva-Maria Plessl ist Teil des vom FWF bewilligten Projekts "PeptAIDes", welches auf dem Gebiet der präklinischen Entwicklung von Peptidtherapeutika arbeitet mit dem Ziel, eine innovative Plattform für interdisziplinäre Wirkstoffentwicklung aufzubauen, neue therapeutische Ansätze zu entwickeln und Arzneistoffkandidaten für die weitere klinische Entwicklung zur Verfügung zu stellen."

Ein Rosiglitazon-Molekül gebunden an einen Ionenkanal. Anna Weinzinger und ihr Team nutzten diesen Arzneistoff, um neue Therapiemöglichkeiten für seltene Ionenkanalerkrankungen zu finden (© Anna Weinzinger).